Positive results from Alzheimer's drug in Phase 1 clinical trial extension

Positive results from Alzheimer's drug in Phase 1 clinical trial extension:

Dementia Big
The pharmaceutical company Biogen has today announced the results of an extended phase 1b clinical trial of the potential Alzheimer’s disease drug, aducanumab. Results from the extended early stage trial, were announced today at Clinical Trials in Alzheimer’s Disease (CTAD) conference in Boston.

http://ift.tt/2zdvXi8